We value your privacy
We use cookies to analyze site traffic and improve your experience. See our Privacy Policy.
Part of Daiichi Sankyo Co., Ltd.
Clinical Trials
65
6 active
Approvals
93
Total approvals
Agencies
1
Regulatory bodies
Founded
1967
Active, not recruiting
6
9.2%
Completed
45
69.2%
Recruiting
Terminated
3
4.6%
Withdrawn
5
7.7%
FDA
Food and Drug Administration
- American Regent, Inc. has issued a voluntary nationwide recall of one lot of Papaverine Hydrochloride Injection, USP, 60 mg/2 mL due to the presence of glass and/or paraformaldehyde particulate matter. - The contaminated particulate matter could travel through blood vessels and block vessels in the heart, lungs, or brain, potentially causing stroke or death. - Lot #25202 was distributed nationwide beginning September 30, 2025, with an expiration date of November 30, 2026, and no adverse events have been reported to date. - Healthcare facilities and consumers are instructed to stop using the recalled product immediately and return it to the place of purchase or discard it.